慢性肾脏病儿童和青少年健康相关生活质量的纵向评估
在澳大利亚和新西兰开展的多中心纵向队列研究,对377例6-18岁慢性肾脏病(CKD)1-5期(透析前)、透析或移植患儿每两年随访一次、共四年,用麦克马斯特健康效用指数标记3评估健康相关生活质量(HRQoL)的多属性效用(MAU)评分轨迹。基线透析患儿中超过半数在第四年末接受了肾移植,其MAU评分平均每年增加0.05(95%CI 0.01至0.09);基线和第二年MAU评分平均差为0.09(95%CI -0.05至0.23,Cohen's d效应量0.31)。基线CKD 1-5期和移植受者疾病分期或治疗方式无变化,HRQoL随时间保持稳定。
要点
- 基线透析患儿中超过半数在第四年末接受肾移植,其MAU评分平均每年增加0.05(95%CI 0.01至0.09)。
- 基线CKD 1-5期和移植受者疾病分期或治疗方式无变化,HRQoL随时间保持稳定。
- 基线CKD分期与随访时间存在交互作用,提示不同基线CKD分期患儿的HRQoL评分斜率不同。
核心结论
- 基线透析患儿HRQoL随时间的改善可能由透析向移植的转换驱动;基线CKD 1-5期和移植受者HRQoL随时间保持稳定。
研究设计与样本
- 在澳大利亚和新西兰开展的多中心纵向队列研究,共纳入377例6-18岁CKD 1-5期(透析前)、透析或移植患儿,每两年随访一次、共四年;用麦克马斯特健康效用指数标记3测量MAU评分,用多变量线性混合模型评估199例CKD 1-5期、43例透析和135例肾移植受者的HRQoL轨迹。
主要发现
- 基线透析患儿中超过半数在第四年末接受肾移植,其MAU评分平均每年增加0.05(95%CI 0.01至0.09),与基线移植受者相比。
- 基线和第二年MAU评分平均差为0.09(95%CI -0.05至0.23),Cohen's d效应量0.31。
- 基线CKD分期与随访时间存在交互作用,提示不同基线CKD分期患儿的HRQoL评分斜率不同。
- 基线CKD 1-5期和移植受者疾病分期或治疗方式无变化,HRQoL随时间保持稳定。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this multi-center longitudinal cohort study conducted in Australia and New Zealand, we assessed the trajectories of health-related quality of life (HRQoL) in children with chronic kidney disease (CKD) over time. A total of 377 children (aged 6-18 years) with CKD stages 1-5 (pre-dialysis), dialysis, or transplant, were followed biennially for four years. Multi Attribute Utility (MAU) scores of HRQoL were measured at baseline and at two and four years using the McMaster Health Utilities Index Mark 3 tool, a generic multi-attribute, preference-based system. A multivariable linear mixed model was used to assess the trajectories of HRQoL over time in 199 children with CKD stage 1-5, 43 children receiving dialysis and 135 kidney transplant recipients. An interaction between CKD stage at baseline and follow-up time indicated that the slopes of the HRQoL scores differed between children by CKD stage at inception. Over half of the cohort on dialysis at baseline had received a kidney transplant by the end of year four and the MAU scores of these children increased by a meaningful amount averaging 0.05 (95% confidence interval 0.01 to 0.09) per year in comparison to those who were transplant recipients at baseline. The mean difference between baseline and year two MAU scores was 0.09 (95% confidence interval -0.05, 0.23), (Cohen's d effect size 0.31). Thus, improvement in HRQoL over time of children on dialysis at baseline was likely to have been driven by their transition from dialysis to transplantation. Additionally, children with CKD stage 1-5 and transplant recipients at baseline had no changes in their disease stage or treatment modality and experienced stable HRQoL over time.
引用
- Guha C, van Zwieten A, Khalid R, et al. Longitudinal assessment of the health-related quality of life of children and adolescents with chronic kidney disease. Kidney Int. 2022. PMID: 36374824. doi:10.1016/j.kint.2022.09.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。